The average one-year price target for Annovis Bio (NYSE:ANVS) has been revised to $10.71 per share as of September 11, 2026, reflecting a 16.67% decrease from the prior estimate of $12.85. The target range spans from a low of $7.07 to a high of $17.85, indicating an expected increase of 823.28% from the latest closing price of $1.16 on September 14, 2026.
Annovis Bio, focused on neurodegenerative diseases like Alzheimer’s and Parkinson’s, reported an actual EPS of -0.4 against an estimated EPS of -0.4624 on August 14, 2026, with no revenue recorded. The stock has seen a decline of 16.55% over the past week and 37.30% over the past month. Analyst sentiment shows 2 strong buy, 6 buy, and 1 hold recommendations as of September 1, 2026. Recent ratings included a maintained Buy from Roth Capital on August 28, 2026, and another from Canaccord Genuity on August 18, 2026.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
